Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

YS Biopharma Reports H1 Loss Per Shae Of $(0.26); Net Loss $(24.3)M

Author: Benzinga Newsdesk | January 22, 2024 06:08pm

As of September 30, 2023, the company had cash and cash equivalents of RMB259.9 million ($36.2 million), compared with RMB370.4 million as of March 31, 2023.

Posted In: YS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist